Clinical Trials Browser

Phase 3 × Breast Neoplasms × Lapatinib × Clear all

NCT03523585 2026-02-27

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

Phase 3 Completed

608 enrolled 17 charts

Breast

Breast Neoplasms

NCT00770809 2025-08-15

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Phase 3 Completed

305 enrolled 10 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01526369 2025-05-09

TH V THL

Phase 3 Completed

75 enrolled

Breast

Breast Neoplasms

NCT00490139 2025-03-21

ALTTO

Phase 3 Completed

8,381 enrolled 22 charts

Breast

Breast Neoplasms

NCT00667251 2025-03-21

Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

Phase 3 Completed

652 enrolled 50 charts

Breast

Breast Neoplasms

NCT01160211 2025-03-07

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Phase 3 Completed

369 enrolled 19 charts

Breast

Breast Neoplasms

NCT01619111 2024-06-04

DETECT III

Phase 3 Completed

105 enrolled

Breast

Breast Neoplasms, Neoplastic Cells, Circulating

NCT03262935 2023-10-19

TULIP

Phase 3 Completed

437 enrolled 17 charts

Breast

Breast Neoplasms

NCT03084939 2023-05-06

Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer

Phase 3 Completed

351 enrolled

Breast

Breast Neoplasms

NCT00272987 2023-04-28

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

Phase 3 Terminated

63 enrolled 22 charts

Breast

Breast Neoplasms

NCT00281658 2023-02-10

Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2

Phase 3 Completed

444 enrolled 28 charts

Breast

Breast Neoplasms

NCT00508274 2021-09-21

Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China

Phase 3 Terminated

52 enrolled 12 charts

Breast

Breast Neoplasms

NCT00553358 2021-09-21

Neo ALTTO

Phase 3 Completed

455 enrolled 34 charts

Breast

Breast Neoplasms, Osteitis Deformans

NCT00073528 2021-02-24

Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

Phase 3 Completed

1,286 enrolled 41 charts

Breast

Breast Neoplasms

NCT00390455 2019-12-20

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Phase 3 Completed

295 enrolled 18 charts

Breast

Breast Neoplasms

NCT00820222 2019-04-02

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer

Phase 3 Completed

540 enrolled 18 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT01104571 2018-09-17

EPHOS-B

Phase 3 Unknown

257 enrolled

Breast

Breast Neoplasms

NCT00829166 2016-10-31

EMILIA

Phase 3 Completed

991 enrolled 26 charts

Breast

Breast Neoplasms

NCT02394496 2016-06-15

OVER

Phase 3 Unknown

396 enrolled

Breast

Breast Neoplasms

NCT00320385 2016-02-26

Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer

Phase 3 Completed

296 enrolled 13 charts

Breast

Breast Neoplasms

NCT00567554 2016-02-10

GeparQuinto

Phase 3 Completed

2,600 enrolled

Breast

Breast Neoplasms

NCT00075270 2015-05-06

Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer

Phase 3 Completed

580 enrolled 27 charts

Breast

Breast Neoplasms

NCT00374322 2014-08-18

Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer

Phase 3 Completed

3,166 enrolled 18 charts

Breast

Breast Neoplasms

NCT00688194 2013-08-26

Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy

Phase 3 Unknown

396 enrolled

Breast

Breast Neoplasms

NCT00078572 2010-12-13

Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer

Phase 3 Completed

408 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis